Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA approval of an ANDA application for eltrombopag olamine generic formulation; regulatory action rather than clinical evidence of efficacy or comparative benefit.
FDA approval of a generic eltrombopag olamine formulation; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative benefit data.